Pityriasis following COVID-19 vaccinations: a systematic review
https://doi.org/10.4081/dr.2023.9742
Supplementary Material: 13
HTML: 1
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
In the wake of a global COVID-19 pandemic, where innovations in vaccination technology and the speed of development and distribution have been unprecedented, a wide variety of post-vaccination cutaneous reactions have surfaced. However, there has not been a systematic review that investigates pityriasis eruptions and the associated variants following COVID-19 inoculations. A PubMed search using Preferred Reporting Items for Systematic Reviews and Meta-Analyses was performed to find case reports from the earliest record through November 2022. Data including types of vaccination and pityriasis were extracted and a quality review was performed; 47 reports with 94 patients were found: 64.9% had pityriasis rosea (PR), 3.2% PR-like eruptions, 16.0% pityriasis rubra pilaris, 7.4% pityriasis lichenoides et varioliformis acuta, 3.2% pityriasis lichenoides chronica, and 5.3% had reactions described as atypical. The top three COVID-19 vaccinations reported were Pfizer-BioNTech (47.9%), Oxford-AstraZeneca (11.7%), and Moderna (8.5%). Pityriasis reactivity was reported most frequently after the Pfizer-BioNTech vaccination, with pityriasis rosea being the most common variant. A large difference was additionally found between the ratio of post-vaccination pityriasis reactions following Pfizer and Moderna vaccinations (5.63), and the ratio of Pfizer’s usage in the United States as of December 28, 2022 relative to that of Moderna (1.59). Further studies with adequate follow-up periods and diagnostic testing will thus need to be performed to elucidate the root of this discrepancy and better characterize the association between different pityriasis reactions and COVID-19 vaccinations.
Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6(1):104. DOI: https://doi.org/10.1038/s41541-021-00369-6
Grieco T, Maddalena P, Sernicola A, Muharremi R, Basili S, Alvaro D, et al. Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study. Dermatol Ther. 2021;34(6):e15153. DOI: https://doi.org/10.1111/dth.15153
Sun Q, Fathy R, McMahon DE, Freeman EE. COVID-19 Vaccines and the Skin: The Landscape of Cutaneous Vaccine Reactions Worldwide. Dermatol Clin. 2021;39(4):653-73. DOI: https://doi.org/10.1016/j.det.2021.05.016
Urbina F, Das A, Sudy E. Clinical variants of pityriasis rosea. World J Clin Cases. 2017;5(6):203-11. DOI: https://doi.org/10.12998/wjcc.v5.i6.203
Brown F, Badri T. Pityriasis Rubra Pilaris. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022.
Wood GS. Other Papulosquamous Disorders. Dermatology. Fourth ed: Elsevier; 2018. p. 163-5.
Sankararaman S, Velayuthan S. Multiple recurrences in pityriasis rosea - a case report with review of the literature. Indian J Dermatol. 2014;59(3):316. DOI: https://doi.org/10.4103/0019-5154.131457
MacGillivray ME, Fiorillo L. Recurrent Pityriasis Rubra Pilaris: A Case Report. J Cutan Med Surg. 2018;22(6):624-6. DOI: https://doi.org/10.1177/1203475418775378
Bellinato F, Maurelli M, Gisondi P, Girolomoni G. A systematic review of treatments for pityriasis lichenoides. J Eur Acad Dermatol Venereol. 2019;33(11):2039-49. DOI: https://doi.org/10.1111/jdv.15813
Gambichler T, Scheel CH, Arafat Y, Kautz O, Boms S. Erythrodermic pityriasis rubra pilaris after SARS-CoV-2 vaccination with concomitant COVID-19 infection. J Eur Acad Dermatol Venereol. 2022;36(9):e675-e6. DOI: https://doi.org/10.1111/jdv.18214
Hlaca N, Zagar T, Kastelan M, Peternel S, Brajac I, Dujmovic-Hasanbegovic K, et al. Pityriasis rubra pilaris following booster dose of mRNA (Pfizer-BioNTech) COVID-19 vaccine. Dermatol Ther. 2022;35(11):e15791. DOI: https://doi.org/10.1111/dth.15791
Sechi A, Pierobon E, Pezzolo E, Germi L, Trevisan G, Zardo D, et al. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Clin Exp Dermatol. 2022;47(2):437-40. DOI: https://doi.org/10.1111/ced.14970
Criado PR, Ianhez M, Rocha PS, Miot HA. Pityriasis rubra pilaris (type I) following ChAdOx1 COVID-19 vaccine: A report of two cases with successful treatment with oral isotretinoin. J Eur Acad Dermatol Venereol. 2022;36(7):e508-e10. DOI: https://doi.org/10.1111/jdv.18055
Palmén J, Lepistö M, Talve L, Hieta N. Pityriasis lichenoides et varioliformis acuta following COVID-19 mRNA vaccination. J Eur Acad Dermatol Venereol. 2022;36(5):e327-e8. DOI: https://doi.org/10.1111/jdv.17912
Sahni MK, Roy K, Asati DP, Khurana U. An old entity, a new trigger: Post COVID-19 vaccine pityriasis rubra pilaris. Int J Risk Saf Med. 2021;32(4):261-4. DOI: https://doi.org/10.3233/JRS-210048
Liu YT, Wang SS. Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination. Skin Health Dis. 2022:e139. DOI: https://doi.org/10.1002/ski2.139
Fernandez LT, Perez-Garza DM, dela OEA, Yamallel-Ortega LA, Cuellar-Barboza A, Ocampo-Candiani J, et al. Pityriasis rubra pilaris in association with inactivated SARS-CoV-2 vaccine (CoronaVac). Dermatol Ther. 2022;35(6):e15455. DOI: https://doi.org/10.1111/dth.15455
Hunjan MK, Roberts C, Karim S, Hague J. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine. Clin Exp Dermatol. 2022;47(1):188-90. DOI: https://doi.org/10.1111/ced.14878
LeWitt T, Chung C, Manton J, Sergeyenko A, Tan T, Sigal A, et al. Rare lymphomatoid reactions following SARS-CoV-2 vaccination. JAAD Case Rep. 2022;20:26-30. DOI: https://doi.org/10.1016/j.jdcr.2021.11.021
Cohen OG, Clark AK, Milbar H, Tarlow M. Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine. Hum Vaccin Immunother. 2021;17(11):4097-8. DOI: https://doi.org/10.1080/21645515.2021.1963173
Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: A case series. Dermatol Ther. 2022;35(2):e15225. DOI: https://doi.org/10.1111/dth.15225
Cyrenne BM, Al-Mohammedi F, DeKoven JG, Alhusayen R. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine. J Eur Acad Dermatol Venereol. 2021;35(9):e546-e8. DOI: https://doi.org/10.1111/jdv.17342
Leerunyakul K, Pakornphadungsit K, Suchonwanit P. Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination. Front Med (Lausanne). 2021;8:752443. DOI: https://doi.org/10.3389/fmed.2021.752443
Llado I, Butron B, Sampedro-Ruiz R, Fraga J, de Argila D. Pityriasis rubra pilaris after Vaxzevria(R) COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(12):e833-e5. DOI: https://doi.org/10.1111/jdv.17542
Adya KA, Inamadar AC, Albadri W. Post Covid-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male. Dermatol Ther. 2021;34(5):e15040. DOI: https://doi.org/10.1111/dth.15040
Wang CS, Chen HH, Liu SH. Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review. J Formos Med Assoc. 2022;121(5):1003-7. DOI: https://doi.org/10.1016/j.jfma.2021.12.028
Pedrazini MC, da Silva MH. Pityriasis rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-AstraZeneca vaccine: Case report and brief literature review. Dermatol Ther. 2021;34(6):e15129. DOI: https://doi.org/10.1111/dth.15129
Khattab E, Christaki E, Pitsios C. Pityriasis Rosea Induced by COVID-19 Vaccination. Eur J Case Rep Intern Med. 2022;9(2):003164. DOI: https://doi.org/10.12890/2022_003164
Al Muqrin AM, Alruwaili ZMN. Pityriasis lichenoides chronica induced by COVID-19 messenger RNA vaccination. JAAD Case Rep. 2022;27:52-4. DOI: https://doi.org/10.1016/j.jdcr.2022.07.017
Bin Rubaian NF, Almuhaidib SR, Aljarri SA, Alamri AS. Pityriasis Rosea Following Pfizer-BioNTech Vaccination in an Adolescent Girl. Cureus. 2022;14(7):e27108. DOI: https://doi.org/10.7759/cureus.27108
Buckley JE, Landis LN, Rapini RP. Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature. JAAD Int. 2022;7:164-8. DOI: https://doi.org/10.1016/j.jdin.2022.01.009
Busto-Leis JM, Servera-Negre G, Mayor-Ibarguren A, Sendagorta-Cudos E, Feito-Rodriguez M, Nuno-Gonzalez A, et al. Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. J Eur Acad Dermatol Venereol. 2021;35(8):e489-e91. DOI: https://doi.org/10.1111/jdv.17301
Carballido Vazquez AM, Morgado B. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination. Br J Dermatol. 2021;185(2):e34. DOI: https://doi.org/10.1111/bjd.20143
Dawoud NM, Aslam H, Ali IM, Dawoud MM. The first case report of Pityriasis lichenoides chronica following COVID-19 mRNA vaccination. Dermatol Ther. 2022;35(6):e15445. DOI: https://doi.org/10.1111/dth.15445
Drago F, Ciccarese G, Guadagno A, Parodi A. Pityriasis lichenoides chronica after BNT162b2 Pfizer-BioNTech vaccine: A novel cutaneous reaction after SARS-CoV-2 vaccine. J Eur Acad Dermatol Venereol. 2022;36(12):e979-e81. DOI: https://doi.org/10.1111/jdv.18418
Gamonal SBL, Marques NCV, Pereira HMB, Gamonal ACC. Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID-19 vaccine: Successful treatment with ustekinumab and acitretin. Dermatol Ther. 2022;35(12):e15899. DOI: https://doi.org/10.1111/dth.15899
Makila T, Jeskanen L, Butina M, Harjama L, Ranki A, Malkonen T, et al. Pityriasis lichenoides et varioliformis acuta after SARS-CoV-2 infection and relapse after vaccination. J Eur Acad Dermatol Venereol. 2022;36(6):e431-e3. DOI: https://doi.org/10.1111/jdv.18024
Marcantonio-Santa Cruz OY, Vidal-Navarro A, Pesque D, Gimenez-Arnau AM, Pujol RM, Martin-Ezquerra G. Pityriasis rosea developing after COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2021;35(11):e721-e2. DOI: https://doi.org/10.1111/jdv.17498
Ramot Y, Nanova K, Faitatziadou SM, Assab DA, Berkun Y, Zlotogorski A. Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2. J Dtsch Dermatol Ges. 2022;20(8):1123-4. DOI: https://doi.org/10.1111/ddg.14784
Sernicola A, Dybala A, Gomes V, Maddalena P, Adotti F, Soda G, et al. Lymphomatoid drug reaction developed after BNT162b2 (Comirnaty) COVID-19 vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption. J Eur Acad Dermatol Venereol. 2022;36(3):e172-e4. DOI: https://doi.org/10.1111/jdv.17807
Temiz SA, Abdelmaksoud A, Dursun R, Durmaz K, Sadoughifar R, Hasan A. Pityriasis rosea following SARS-CoV-2 vaccination: A case series. J Cosmet Dermatol. 2021;20(10):3080-4. DOI: https://doi.org/10.1111/jocd.14372
Valk B, Bender B. Pityriasis Rosea Associated With COVID-19 Vaccination: A Common Rash Following Administration of a Novel Vaccine. Cutis. 2021;108(6):317-8. DOI: https://doi.org/10.12788/cutis.0411
Filippi F, Baraldi C, Zinzani PL, Casadei B, Pileri A. A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2022;36(10):e747-e9. DOI: https://doi.org/10.1111/jdv.18269
Mehta H, Handa S, Malhotra P, Patial M, Gupta S, Mukherjee A, et al. Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India. J Eur Acad Dermatol Venereol. 2022;36(1):e16-e8. DOI: https://doi.org/10.1111/jdv.17678
Wada M, Lee S, Curnow P, Simpson I, Mar A. A case of pityriasis rubra pilaris following AstraZeneca COVID-19 vaccine. JAAD Case Rep. 2022;24:74-7. DOI: https://doi.org/10.1016/j.jdcr.2022.04.020
Ajebo EM, Howard JD, Anand D, Davis LS. Pityriasis rubra pilaris potentially triggered by messenger RNA-1273 COVID vaccine. JAAD Case Rep. 2022;23:114-6. DOI: https://doi.org/10.1016/j.jdcr.2022.03.013
Shin SH, Hong JK, Hong SA, Li K, Yoo KH. Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination. Int J Infect Dis. 2022;114:88-9. DOI: https://doi.org/10.1016/j.ijid.2021.10.055
Akdas E, Ilter N, Ogut B, Erdem O. Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol. 2021;35(8):e491-e3. DOI: https://doi.org/10.1111/jdv.17316
Gokcek GE, Oksum Solak E, Colgecen E. Pityriasis rosea like eruption: A dermatological manifestation of Coronavac-COVID-19 vaccine. Dermatol Ther. 2022;35(2):e15256. DOI: https://doi.org/10.1111/dth.15256
Shakoei S, Kalantari Y, Nasimi M, Tootoonchi N, Ansari MS, Razavi Z, et al. Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases. Dermatol Ther. 2022;35(8):e15651. DOI: https://doi.org/10.1111/dth.15651
Huang L, Yao Z, Zhang J. Two cases of pityriasis rosea after the injection of coronavirus disease 2019 vaccine. J Eur Acad Dermatol Venereol. 2022;36(1):e9-e11. DOI: https://doi.org/10.1111/jdv.17648
Fenner B, Marquez JL, Pham M, Tarbox M. Inverse pityriasis rosea secondary to COVID-19 vaccination. Proc (Bayl Univ Med Cent). 2022;35(3):342-3. DOI: https://doi.org/10.1080/08998280.2022.2044742
Singh B, Kar BR, Agrawal I. Pityriasis Rosea Following Covaxin (BBV152) Vaccination for COVID-19. Indian Dermatol Online J. 2022;13(5):653-4. DOI: https://doi.org/10.4103/idoj.IDOJ_576_21
Bostan E, Jarbou A. Atypical pityriasis rosea associated with mRNA COVID-19 vaccine. J Med Virol. 2022;94(3):814-6. DOI: https://doi.org/10.1002/jmv.27364
Abdullah L, Hasbani D, Kurban M, Abbas O. Pityriasis rosea after mRNA COVID-19 vaccination. Int J Dermatol. 2021;60(9):1150-1. DOI: https://doi.org/10.1111/ijd.15700
Dormann H, Grummt S, Karg M. Pityriasis Rosea as a Possible Complication of Vaccination Against COVID-19. Dtsch Arztebl Int. 2021;118(25):431. DOI: https://doi.org/10.3238/arztebl.m2021.0257
McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. Journal of the American Academy of Dermatology. 2021;85(1):46-55. DOI: https://doi.org/10.1016/j.jaad.2021.03.092
Temiz SA, Abdelmaksoud A, Wollina U, Kutlu O, Dursun R, Patil A, et al. Cutaneous and Allergic reactions due to COVID-19 vaccinations: A review. Journal of Cosmetic Dermatology. 2022;21(1):4-12. DOI: https://doi.org/10.1111/jocd.14613
Qaderi K, Golezar MH, Mardani A, Mallah MA, Moradi B, Kavoussi H, et al. Cutaneous adverse reactions of COVID-19 vaccines: A systematic review. Dermatol Ther. 2022;35(5):e15391. DOI: https://doi.org/10.1111/dth.15391
Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. J Clin Med. 2021;10(22). DOI: https://doi.org/10.3390/jcm10225344
Castro BA, Pereira JM, Meyer RL, Trindade FM, Pedrosa MS, Piancastelli AC. Pityriasis lichenoides et varioliformis acuta after influenza vaccine. An Bras Dermatol. 2015;90(3 Suppl 1):181-4. DOI: https://doi.org/10.1590/abd1806-4841.20153492
Engelmann C, Elsner P, Miguel D. Treatment of pityriasis rubra pilaris type I: a systematic review. Eur J Dermatol. 2019;29(5):524-37. DOI: https://doi.org/10.1684/ejd.2019.3641
Drago F, Ciccarese G, Parodi A. Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them? JAAD Case Rep. 2018;4(8):800-1. DOI: https://doi.org/10.1016/j.jdcr.2018.04.002
Broccolo F, Drago F, Careddu AM, Foglieni C, Turbino L, Cocuzza CE, et al. Additional Evidence that Pityriasis Rosea Is Associated with Reactivation of Human Herpesvirus-6 and -7. Journal of Investigative Dermatology. 2005;124(6):1234-40. DOI: https://doi.org/10.1111/j.0022-202X.2005.23719.x
De A, Roy S, Sukla S, Ansari A, Biswas S. Occult Hepatitis B Virus Infections (Often with Human Herpesvirus 7 Co-Infection) Detected in Pityriasis rosea Patients: A Pilot Study. Indian J Dermatol. 2017;62(6):598-605. DOI: https://doi.org/10.4103/ijd.IJD_235_17
Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(9):e436-e7. DOI: https://doi.org/10.1111/jdv.16579
Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol. 2021;93(4):1850-1. DOI: https://doi.org/10.1002/jmv.26549
Drago F, Ciccarese G, Rebora A, Parodi A. Pityriasis rosea following human papillomavirus vaccination. Braz J Infect Dis. 2015;19(2):224-5. DOI: https://doi.org/10.1016/j.bjid.2014.10.006
Kaplan B, Grunwald MH, Halevy S. Pityriasis rosea-like eruption associated with BCG vaccination. Isr J Med Sci. 1989;25(10):570-2.
Witherspoon FG, Thibodaux DJ. Pityriasis-rosea-like eruption following smallpox vaccination. AMA Arch Derm. 1957;76(1):109-10. DOI: https://doi.org/10.1001/archderm.1957.01550190113025
De Keyser F, Naeyaert JM, Hindryckx P, Elewaut D, Verplancke P, Peene I, et al. Immune-mediated pathology following hepatitis B vaccination. Two cases of polyarteritis nodosa and one case of pityriasis rosea-like drug eruption. Clin Exp Rheumatol. 2000;18(1):81-5.
Sasmaz S, Karabiber H, Boran C, Garipardic M, Balat A. Pityriasis rosea-like eruption due to pneumococcal vaccine in a child with nephrotic syndrome. J Dermatol. 2003;30(3):245-7. DOI: https://doi.org/10.1111/j.1346-8138.2003.tb00380.x
Brzezinski P, Chiriac A. Uncommon presentation of pityriasis rosea after yellow fever inoculation. JAMA Dermatol. 2014;150(9):1020-1. DOI: https://doi.org/10.1001/jamadermatol.2013.10505
Papakostas D, Stavropoulos PG, Papafragkaki D, Grigoraki E, Avgerinou G, Antoniou C. An atypical case of pityriasis rosea gigantea after influenza vaccination. Case Rep Dermatol. 2014;6(1):119-23. DOI: https://doi.org/10.1159/000362640
Chen JF, Chiang CP, Chen YF, Wang WM. Pityriasis rosea following influenza (H1N1) vaccination. J Chin Med Assoc. 2011;74(6):280-2. DOI: https://doi.org/10.1016/j.jcma.2011.04.010
Mohamed M, Belhadjali H, Hammedi F, Ben Meriem C, Zili J. Pityriasis rubra pilaris occurring after vaccination with diphtheria-pertussis-tetanus and oral poliovirus vaccines. Indian J Dermatol Venereol Leprol. 2015;81(6):618-20. DOI: https://doi.org/10.4103/0378-6323.168326
Jastrząb BA, Stefaniak AA, Hryncewicz-Gwóźdź A, Nockowski P, Szepietowski JC. Pityriasis Lichenoides et Varioliformis Acuta Triggered by Human Papillomavirus Vaccine: A Case Report and Literature Review. Acta Derm Venereol. 2021;101(9):adv00552. DOI: https://doi.org/10.2340/00015555-3921
Filippi F, Patrizi A, Sabattini E, Varotti E, Bertuzzi C, Pileri A. Pityriasis lichenoides triggered by measles-mumps-rubella vaccine injection. J Dtsch Dermatol Ges. 2020;18(7):758-60. DOI: https://doi.org/10.1111/ddg.14153
Gunatheesan S, Ferguson J, Moosa Y. Pityriasis lichenoides et varioliformis acuta: a rare association with the measles, mumps and rubella vaccine. Australas J Dermatol. 2012;53(4):e76-8. DOI: https://doi.org/10.1111/j.1440-0960.2011.00781.x
Shastry V, Ranugha PSS, Rangappa V, Sanjaykumar P. Pityriasis lichenoides et varioliformis acuta following measles rubella vaccine. Indian J Dermatol Venereol Leprol. 2020;86(4):398-400. DOI: https://doi.org/10.4103/ijdvl.IJDVL_48_18
Gil-Bistes D, Kluger N, Bessis D, Guillot B, Raison-Peyron N. Pityriasis lichenoides chronic after measles-mumps-rubella vaccination. J Dermatol. 2012;39(5):492-3. DOI: https://doi.org/10.1111/j.1346-8138.2011.01380.x
Merlotto MR, Bicudo NP, Marques MEA, Marques SA. Pityriasis lichenoides et varioliformis acuta following anti-tetanus and diphtheria adult vaccine. An Bras Dermatol. 2020;95(2):259-60. DOI: https://doi.org/10.1016/j.abd.2019.06.009
Rijkers GT, Weterings N, Obregon-Henao A, Lepolder M, Dutt TS, van Overveld FJ, et al. Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines (Basel). 2021;9(8). DOI: https://doi.org/10.3390/vaccines9080848
Ritchie Hannah ME, Rodes-Guirao Lucas, Appel Cameron, Gavrilov Daniel. Coronavirus Pandemic (COVID-19) [Available from: https://ourworldindata.org/coronavirus.
Larson V, Seidenberg R, Caplan A, Brinster NK, Meehan SA, Kim RH. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol. 2022;49(1):34-41. DOI: https://doi.org/10.1111/cup.14104
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
